Jointown(SH:600998) 智通财经网·2025-10-16 11:07Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Information - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] - Glycopyrrolate is indicated for the treatment of gastric and duodenal ulcers, chronic gastritis, and for maintenance bronchial dilation therapy in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]